Fractyl Health (NASDAQ:GUTS) Stock Price Down 6.2%

Fractyl Health, Inc. (NASDAQ:GUTS)’s stock price was down 6.2% during trading on Wednesday . The company traded as low as $7.10 and last traded at $7.20. Approximately 154,712 shares changed hands during trading, a decline of 63% from the average daily volume of 422,425 shares. The stock had previously closed at $7.68.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on GUTS shares. Morgan Stanley started coverage on Fractyl Health in a report on Tuesday, February 27th. They set an “overweight” rating and a $18.00 target price on the stock. Evercore ISI started coverage on Fractyl Health in a report on Wednesday, February 28th. They set an “outperform” rating on the stock. Finally, Bank of America initiated coverage on Fractyl Health in a report on Tuesday, February 27th. They set a “buy” rating and a $26.00 target price on the stock.

Fractyl Health Stock Performance

Insider Activity at Fractyl Health

In related news, Director Ajay Royan acquired 333,333 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were bought at an average cost of $15.00 per share, with a total value of $4,999,995.00. Following the completion of the transaction, the director now directly owns 1,251,900 shares of the company’s stock, valued at approximately $18,778,500. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.